IDEAYA Biosciences (NASDAQ:IDYA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of IDEAYA Biosciences (NASDAQ:IDYA) from a sell rating to a hold rating in a research note issued to investors on Saturday.

Several other research analysts also recently weighed in on IDYA. New Street Research set a $30.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, October 21st. BTIG Research reaffirmed a “buy” rating and set a $62.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, October 21st. Citizens Jmp started coverage on shares of IDEAYA Biosciences in a research note on Thursday, September 4th. They set a “mkt outperform” rating and a $41.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Wednesday, October 8th. Finally, JMP Securities started coverage on shares of IDEAYA Biosciences in a research note on Thursday, September 4th. They set a “market outperform” rating and a $41.00 price objective for the company. Fourteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, IDEAYA Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $44.13.

IDEAYA Biosciences Trading Down 1.6%

Shares of IDYA stock opened at $31.36 on Friday. The firm has a 50-day moving average price of $27.10 and a 200 day moving average price of $23.45. IDEAYA Biosciences has a twelve month low of $13.45 and a twelve month high of $33.64. The company has a market capitalization of $2.75 billion, a price-to-earnings ratio of -8.27 and a beta of 0.14.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The company had revenue of $6.00 million for the quarter, compared to analysts’ expectations of $3.48 million. During the same period last year, the firm earned ($0.68) earnings per share. The company’s revenue was up NaN% compared to the same quarter last year. As a group, research analysts predict that IDEAYA Biosciences will post -3.07 earnings per share for the current year.

Hedge Funds Weigh In On IDEAYA Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. CWM LLC boosted its holdings in IDEAYA Biosciences by 325.7% in the 1st quarter. CWM LLC now owns 2,371 shares of the company’s stock worth $39,000 after acquiring an additional 1,814 shares during the period. PNC Financial Services Group Inc. boosted its holdings in IDEAYA Biosciences by 180.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company’s stock worth $39,000 after acquiring an additional 1,546 shares during the period. Signaturefd LLC boosted its holdings in IDEAYA Biosciences by 374.8% in the 1st quarter. Signaturefd LLC now owns 2,877 shares of the company’s stock worth $47,000 after acquiring an additional 2,271 shares during the period. Elevation Point Wealth Partners LLC purchased a new position in IDEAYA Biosciences in the 2nd quarter worth approximately $61,000. Finally, Daiwa Securities Group Inc. boosted its holdings in IDEAYA Biosciences by 16.1% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after acquiring an additional 436 shares during the period. Hedge funds and other institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.